Although some studies have shown that vimentin expression is a marker for poor prognosis [36], others have reported that its high expression can sensitize triple-negative breast cancer in vitro and in vivo to the c-Src inhibitor (dasatinib) [37,38]. This evidence concerns the gene VIM and triple-negative breast carcinoma.